{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:14:09Z","timestamp":1793394849217,"version":"4.5.0"},"reference-count":163,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.aohep.2026.102180","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:32:18Z","timestamp":1768005138000},"page":"102180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The African Middle East Association of Gastroenterology (AMAGE) clinical practice guidelines for the diagnosis and management of metabolic dysfunction associated fatty liver disease"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7989-5318","authenticated-orcid":false,"given":"Yasser","family":"Fouad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Elwakil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal M.","family":"Sanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olusegun","family":"Ojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer Al","family":"Awadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ponsiano","family":"Ocama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"A Abdelkader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said A.","family":"Al-Busafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaw Asante","family":"Awuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4123-9221","authenticated-orcid":false,"given":"Samy","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maheeba","family":"Abdulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masolwa","family":"Ng'wanasayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebada","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munira Y.","family":"Altarrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mortada H.F.","family":"El-Shabrawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reidwan","family":"Ally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Tahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamardan","family":"Bazeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Ajlouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Aly","family":"Gomaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel-Khalek","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailemichael","family":"Desalegn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2887-8328","authenticated-orcid":false,"given":"Moutaz","family":"Derbala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enas","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmunem A","family":"Abdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriam","family":"Sabbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Mehrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Shahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Amajuoyi","family":"Ndububa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Fares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawel","family":"Afredj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa M","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almoutaz","family":"Hashim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Eletreby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manar Sayed","family":"Farhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Debzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa","family":"Abdeltawab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousry Esam-Eldin","family":"Abo-Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8207-2934","authenticated-orcid":false,"given":"Shaymaa","family":"Nafady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violet","family":"Kayamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Zaghloul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen Abdel","family":"Alem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4242-6232","authenticated-orcid":false,"given":"Doaa","family":"Elwazzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Elwakil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulla Al","family":"Hassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawal","family":"Alkhalidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Sharaf-Eldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Necati","family":"Ormeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Eslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2026.102180_bib0001","doi-asserted-by":"crossref","DOI":"10.1177\/20420188251406531","article-title":"The burden of metabolic diseases in the Arab region, 1990-2021","volume":"16","author":"Pan","year":"2025","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.aohep.2026.102180_bib0002","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jhep.2021.01.015","article-title":"The Sub-Saharan Africa position statement on the redefinition of fatty liver disease: from NAFLD to MAFLD","volume":"74","author":"Spearman","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2026.102180_bib0003","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/j.jhep.2024.01.033","article-title":"Joint position statement from the Middle East and North Africa and Sub-Saharan Africa on continuing to endorse the MAFLD definition","volume":"80","author":"Fouad","year":"2024","journal-title":"J Hepatol"},{"issue":"7308","key":"10.1016\/j.aohep.2026.102180_bib0004","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/bmj.323.7308.334","article-title":"A new system for grading recommendations in evidence based guidelines","volume":"323","author":"Harbour","year":"2001","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.aohep.2026.102180_bib0005","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70088","article-title":"Underrepresentation of Arabs in functional genetics studies: opportunities and obstacles for advancing biology and Human health","volume":"45","author":"Pan","year":"2025","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.aohep.2026.102180_bib0006","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1210\/clinem\/dgac321","article-title":"Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals","volume":"107","author":"Chan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.aohep.2026.102180_bib0007","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/liv.15852","article-title":"Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa","volume":"44","author":"Younossi","year":"2024","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.aohep.2026.102180_bib0008","article-title":"Global burden of metabolic dysfunction-associated liver disease, 2010 to 2021\u2606","volume":"7","author":"Feng","year":"2024","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.aohep.2026.102180_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2024.103043","article-title":"Global prevalence of nonalcoholic fatty liver disease: an updated review meta-analysis comprising a population of 78 million from 38 countries","volume":"55","author":"Amini-Salehi","year":"2024","journal-title":"Arch Med Res"},{"issue":"10","key":"10.1016\/j.aohep.2026.102180_bib0010","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41575-022-00635-5","article-title":"Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight","volume":"19","author":"Eslam","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2026.102180_bib0011","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/apt.17096","article-title":"Meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000\u20132021","volume":"56","author":"Li","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.aohep.2026.102180_bib0012","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2468-1253(21)00183-7","article-title":"Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement","volume":"6","author":"Eslam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0013","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.aohep.2026.102180_bib0014","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.aohep.2026.102180_bib0015","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.aohep.2026.102180_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-024-10774-3","article-title":"The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease","volume":"19","author":"Eslam","year":"2025","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.aohep.2026.102180_bib0017","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/liv.14739","article-title":"The NAFLD-MAFLD debate: eminence vs evidence","volume":"41","author":"Fouad","year":"2021","journal-title":"Liver Int"},{"issue":"12","key":"10.1016\/j.aohep.2026.102180_bib0018","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/liv.14675","article-title":"MAFLD identifies patients with significant hepatic fibrosis better than NAFLD","volume":"40","author":"Yamamura","year":"2020","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.aohep.2026.102180_bib0019","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study","volume":"19","author":"Lee","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.aohep.2026.102180_bib0020","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/hepr.13685","article-title":"MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach","volume":"51","author":"Tsutsumi","year":"2021","journal-title":"Hepatol Res"},{"issue":"3","key":"10.1016\/j.aohep.2026.102180_bib0021","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MOG.0000000000000823","article-title":"Metabolic dysfunction-associated fatty liver disease: a year in review","volume":"38","author":"Alharthi","year":"2022","journal-title":"Curr Opin Gastroenterol"},{"issue":"2","key":"10.1016\/j.aohep.2026.102180_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2023-100019","article-title":"Two years on, a perspective on MAFLD","volume":"1","author":"Eslam","year":"2023","journal-title":"eGastroenterology"},{"issue":"4","key":"10.1016\/j.aohep.2026.102180_bib0023","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/17446651.2025.2492767","article-title":"MASLD: a year in review","volume":"20","author":"Jiang","year":"2025","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.aohep.2026.102180_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.aohep.2024.101573","article-title":"Global multi-societies endorsement of the MAFLD definition","volume":"29","author":"Alboraie","year":"2024","journal-title":"Ann Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2026.102180_bib0025","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S2468-1253(22)00062-0","article-title":"Global multi-stakeholder endorsement of the MAFLD definition","volume":"7","author":"M\u00e9ndez-S\u00e1nchez","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.aohep.2026.102180_bib0026","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2174\/1871530323666221028154159","article-title":"Hepatologists\u2019 awareness and knowledge of NAFLD and the familiarity with renaming NAFLD to MAFLD","volume":"24","author":"Alem","year":"2024","journal-title":"Endocrine, Metab Immune Disord-Drug Targets (Formerly Curr Drug Targets-Immune, Endocr Metab Disord)"},{"issue":"5","key":"10.1016\/j.aohep.2026.102180_bib0027","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jhep.2020.12.035","article-title":"Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists","volume":"74","author":"Fouad","year":"2021","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.aohep.2026.102180_bib0028","doi-asserted-by":"crossref","first-page":"e1077","DOI":"10.1016\/S2214-109X(18)30357-7","article-title":"Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1.9 million participants","volume":"6","author":"Guthold","year":"2018","journal-title":"Lancet Glob Health"},{"issue":"9945","key":"10.1016\/j.aohep.2026.102180_bib0029","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0140-6736(14)60460-8","article-title":"Global, regional, and national prevalence of overweight and obesity in children and adults during 1980\u20132013: a systematic analysis for the global burden of disease study 2013","volume":"384","author":"Ng","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.aohep.2026.102180_bib0030","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.aogh.2015.12.011","article-title":"Epidemiology of and risk factors for type 2 diabetes in Egypt","volume":"81","author":"Hegazi","year":"2015","journal-title":"Ann Glob Health"},{"key":"10.1016\/j.aohep.2026.102180_bib0031","series-title":"IDF Diabetes Atlas Brussels","author":"Federation","year":"2021"},{"issue":"11","key":"10.1016\/j.aohep.2026.102180_bib0032","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S2213-8587(19)30179-2","article-title":"Metabolic health in the Middle East and north Africa","volume":"7","author":"Azizi","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.aohep.2026.102180_bib0033","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.30908","article-title":"Lean NAFLD: a distinct entity shaped by differential metabolic adaptation","volume":"71","author":"Chen","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.aohep.2026.102180_bib0034","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s12072-015-9689-y","article-title":"Genetic and epigenetic mechanisms of NASH","volume":"10","author":"Eslam","year":"2016","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0035","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41575-019-0212-0","article-title":"Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology","volume":"17","author":"Eslam","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0036","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/hep.28475","article-title":"Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes","volume":"64","author":"Eslam","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0037","doi-asserted-by":"crossref","first-page":"7430","DOI":"10.1038\/s41467-022-35158-9","article-title":"A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes","volume":"13","author":"Alharthi","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.aohep.2026.102180_bib0038","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2008.11.005","article-title":"Long-term follow-up of patients with nonalcoholic fatty liver","volume":"7","author":"Rafiq","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2026.102180_bib0039","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.cgh.2022.07.033","article-title":"Disease state transition probabilities across the spectrum of NAFLD: a systematic review and meta-analysis of paired biopsy or imaging studies","volume":"21","author":"Le","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"16","key":"10.1016\/j.aohep.2026.102180_bib0040","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.3748\/wjg.v26.i16.1861","article-title":"Macrophages in metabolic associated fatty liver disease","volume":"26","author":"Alharthi","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"11","key":"10.1016\/j.aohep.2026.102180_bib0041","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1016\/j.cgh.2022.10.039","article-title":"Nonheavy alcohol use associates with liver fibrosis and nonalcoholic steatohepatitis in the framingham heart study","volume":"21","author":"Rice","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"741","key":"10.1016\/j.aohep.2026.102180_bib0042","doi-asserted-by":"crossref","first-page":"eadj0133","DOI":"10.1126\/scitranslmed.adj0133","article-title":"Inhibition of MERTK reduces organ fibrosis in mouse models of fibrotic disease","volume":"16","author":"Pan","year":"2024","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.aohep.2026.102180_bib0043","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s12072-024-10673-7","article-title":"MAFLD identifies patients with significant hepatic fibrosis better than MASLD","volume":"18","author":"Pan","year":"2024","journal-title":"Hepatol Int"},{"issue":"4","key":"10.1016\/j.aohep.2026.102180_bib0044","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2026.102180_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.102104","article-title":"Changing profile and burden of hepatocellular carcinoma in Arab Countries in 1990-2021","volume":"30","author":"Pan","year":"2025","journal-title":"Ann Hepatol"},{"issue":"13","key":"10.1016\/j.aohep.2026.102180_bib0046","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21037\/atm.2017.04.41","article-title":"Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease","volume":"5","author":"Mantovani","year":"2017","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0047","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102180_bib0048","doi-asserted-by":"crossref","DOI":"10.1177\/20420188221145549","article-title":"MAFLD: a multisystem disease","volume":"14","author":"Pipitone","year":"2023","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.aohep.2026.102180_bib0049","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2468-1253(21)00132-1","article-title":"Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases","volume":"6","author":"Eslam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2026.102180_bib0050","first-page":"75","article-title":"MAFLD: a comprehensive review of the link between metabolic dysfunction and cardiovascular risk","volume":"17","author":"Mostafa","year":"2025","journal-title":"Hepat Med"},{"issue":"2","key":"10.1016\/j.aohep.2026.102180_bib0051","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0052","doi-asserted-by":"crossref","first-page":"134","DOI":"10.14218\/JCTH.2021.00248","article-title":"Biomarkers of metabolic (dysfunction)-associated fatty liver disease: an update","volume":"10","author":"Alharthi","year":"2021","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0053","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jhep.2011.03.020","article-title":"Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort","volume":"56","author":"Armstrong","year":"2012","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2026.102180_bib0054","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"Mozes","year":"2022","journal-title":"Gut"},{"issue":"Supplement_1","key":"10.1016\/j.aohep.2026.102180_bib0055","doi-asserted-by":"crossref","DOI":"10.2337\/db18-1570-P","article-title":"Liver fibrosis as assessed by the FIB-4 index in patients with type 2 diabetes (T2DM)","volume":"67","author":"Filozof","year":"2018","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.aohep.2026.102180_bib0056","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Off J Am Coll Gastroenterol| ACG"},{"issue":"13","key":"10.1016\/j.aohep.2026.102180_bib0057","article-title":"Comparing FIB-4, VCTE, pSWE, 2D-SWE, and MRE thresholds and diagnostic accuracies for detecting hepatic fibrosis in patients with MASLD: a systematic review and Meta-analysis","volume":"15","author":"Wilson","year":"2025","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"10.1016\/j.aohep.2026.102180_bib0058","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jhep.2021.12.031","article-title":"Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events","volume":"76","author":"Boursier","year":"2022","journal-title":"J Hepatol"},{"issue":"15","key":"10.1016\/j.aohep.2026.102180_bib0059","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease","volume":"331","author":"Lin","year":"2024","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.aohep.2026.102180_bib0060","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","article-title":"Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis","volume":"8","author":"Mozes","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2026.102180_bib0061","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12072-023-10550-9","article-title":"Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy","volume":"17","author":"Chan","year":"2023","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0062","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S2468-1253(23)00270-4","article-title":"Implementation of a liver health check in people with type 2 diabetes","volume":"9","author":"Abeysekera","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.aohep.2026.102180_bib0063","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","article-title":"Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis","volume":"8","author":"Huang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2026.102180_bib0064","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jhep.2009.09.001","article-title":"Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study","volume":"51","author":"Dasarathy","year":"2009","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2026.102180_bib0065","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.aohep.2026.102180_bib0066","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.cgh.2019.11.060","article-title":"Prospective, same-day, direct comparison of controlled attenuation parameter with the M vs the XL probe in patients with nonalcoholic fatty liver disease, using magnetic resonance imaging-proton density fat fraction as the standard","volume":"18","author":"Caussy","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.aohep.2026.102180_bib0067","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/liv.12226","article-title":"Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)","volume":"33","author":"Verma","year":"2013","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.aohep.2026.102180_bib0068","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/gutjnl-2022-328689","article-title":"Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"72","author":"Ravaioli","year":"2023","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.aohep.2026.102180_bib0069","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.aohep.2026.102180_bib0070","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hep.27173","article-title":"Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease","volume":"60","author":"Bedossa","year":"2014","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.aohep.2026.102180_bib0071","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/MEG.0000000000002583","article-title":"The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: A propensity score matching study","volume":"35","author":"Wang","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2026.102180_bib0072","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/liv.12584","article-title":"The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"35","author":"Petta","year":"2015","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.aohep.2026.102180_bib0073","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2026.102180_bib0074","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S1665-2681(19)31343-2","article-title":"Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables","volume":"12","author":"Eslam","year":"2013","journal-title":"Ann Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2026.102180_bib0075","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/j.gastro.2012.05.035","article-title":"Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis","volume":"143","author":"Colecchia","year":"2012","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.aohep.2026.102180_bib0076","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jhep.2014.02.024","article-title":"Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study","volume":"60","author":"Colecchia","year":"2014","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2026.102180_bib0077","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1148\/radiol.14141210","article-title":"Prospective comparison of spleen and liver stiffness by using shear-wave and transient elastography for detection of portal hypertension in cirrhosis","volume":"275","author":"Elkrief","year":"2015","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.aohep.2026.102180_bib0078","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clinre.2017.11.002","article-title":"Performance of spleen stiffness measurement in prediction of clinical significant portal hypertension: a meta-analysis","volume":"42","author":"Song","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"6","key":"10.1016\/j.aohep.2026.102180_bib0079","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.jhep.2020.06.042","article-title":"Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis","volume":"73","author":"Zheng","year":"2020","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2026.102180_bib0080","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"152","author":"Park","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0081","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/sjg.sjg_357_21","article-title":"The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"28","author":"Fouad","year":"2022","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.aohep.2026.102180_bib0082","doi-asserted-by":"crossref","first-page":"149","DOI":"10.37349\/emed.2020.00011","article-title":"Nonalcoholic fatty liver disease and portal hypertension","volume":"1","author":"Ryou","year":"2020","journal-title":"Explor Med"},{"issue":"3","key":"10.1016\/j.aohep.2026.102180_bib0083","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s12072-023-10526-9","article-title":"MAFLD and chronic kidney disease: two sides of the same coin?","volume":"17","author":"Pan","year":"2023","journal-title":"Hepatol Int"},{"issue":"5","key":"10.1016\/j.aohep.2026.102180_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2024.101512","article-title":"MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease","volume":"29","author":"Pan","year":"2024","journal-title":"Ann Hepatol"},{"issue":"7","key":"10.1016\/j.aohep.2026.102180_bib0085","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/liv.15931","article-title":"MAFLD predicts cardiovascular disease risk better than MASLD","volume":"44","author":"Pan","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2026.102180_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154955","article-title":"Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers","volume":"127","author":"Liu","year":"2022","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.aohep.2026.102180_bib0087","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s42000-022-00391-w","article-title":"Detangling the interrelations between MAFLD, insulin resistance, and key hormones","volume":"21","author":"Pal","year":"2022","journal-title":"Hormones"},{"issue":"6","key":"10.1016\/j.aohep.2026.102180_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101138","article-title":"Metabolic dysfunction: the silenced connection with fatty liver disease","volume":"28","author":"Ram\u00edrez-Mej\u00eda","year":"2023","journal-title":"Ann Hepatol"},{"issue":"8","key":"10.1016\/j.aohep.2026.102180_bib0089","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ajic.2009.12.016","article-title":"Seroprevalence of hepatitis C and B among blood donors in Egypt: Minya Governorate, 2000-2008","volume":"38","author":"Khattab","year":"2010","journal-title":"Am J Infect Control"},{"issue":"11-12","key":"10.1016\/j.aohep.2026.102180_bib0090","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/apt.17233","article-title":"Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection\u2014a population-based study","volume":"56","author":"Attia","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.aohep.2026.102180_bib0091","first-page":"258","article-title":"Hepatitis C Virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of Hepatitis C Virus infection","volume":"10","author":"Khattab","year":"2010","journal-title":"Hepat Mon"},{"issue":"10","key":"10.1016\/j.aohep.2026.102180_bib0092","first-page":"955","article-title":"Research progress of antiviral treatment for patients with chronic hepatitis B combined with metabolic fatty liver disease","volume":"32","author":"Chen","year":"2024","journal-title":"Zhonghua gan zang bing za zhi= Zhonghua ganzangbing zazhi= Chin J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2026.102180_bib0093","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s12072-023-10545-6","article-title":"Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B","volume":"17","author":"Huang","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.aohep.2026.102180_bib0094","series-title":"Global hepatitis report2024: action for access in low-and middle-income countries","year":"2024"},{"issue":"10","key":"10.1016\/j.aohep.2026.102180_bib0095","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/apt.16346","article-title":"MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective","volume":"53","author":"Fouad","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.aohep.2026.102180_bib0096","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/liv.14666","article-title":"GES: A validated simple score to predict the risk of HCC in patients with HCV-GT4-associated advanced liver fibrosis after oral antivirals","volume":"40","author":"Shiha","year":"2020","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.aohep.2026.102180_bib0097","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1080\/17474124.2021.1952867","article-title":"Metabolic-associated fatty liver disease and autoimmune hepatitis: an overlooked interaction","volume":"15","author":"Gaber","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2026.102180_bib0098","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2169\/internalmedicine.3112-23","article-title":"Autoimmune hepatitis with metabolic dysfunction-associated fatty liver disease","volume":"64","author":"Takahashi","year":"2025","journal-title":"Internal Med"},{"issue":"4","key":"10.1016\/j.aohep.2026.102180_bib0099","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2022.04.040","article-title":"Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease","volume":"77","author":"Staufer","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102180_bib0100","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3389\/fmed.2020.00448","article-title":"Non-alcoholic fatty liver disease and alcohol-related liver disease: two intertwined entities","volume":"7","author":"Idalsoaga","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.aohep.2026.102180_bib0101","first-page":"42","article-title":"A comprehensive review of patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease","volume":"4","author":"Aybuke","year":"2024","journal-title":"Metab Target Organ Damage"},{"key":"10.1016\/j.aohep.2026.102180_bib0102","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"issue":"4","key":"10.1016\/j.aohep.2026.102180_bib0103","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0104","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.aohep.2026.102180_bib0105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.aohep.2026.102180_bib0106","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3945\/ajcn.2008.26720","article-title":"Prolonged saturated fat\u2013induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver","volume":"89","author":"Musso","year":"2009","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0107","article-title":"Antioxidant supplements for non-alcoholic fatty liver disease and\/or steatohepatitis","volume":"2007","author":"Lirussi","year":"2007","journal-title":"Cochrane Datab System Rev"},{"issue":"18","key":"10.1016\/j.aohep.2026.102180_bib0108","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2026.102180_bib0109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-016-0638-y","article-title":"No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial","volume":"14","author":"Barchetta","year":"2016","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.aohep.2026.102180_bib0110","doi-asserted-by":"crossref","first-page":"E552","DOI":"10.1152\/ajpendo.00220.2009","article-title":"Effects of exercise training and diet on lipid kinetics during free fatty acid-induced insulin resistance in older obese humans with impaired glucose tolerance","volume":"297","author":"Solomon","year":"2009","journal-title":"Am J Physiol-Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.aohep.2026.102180_bib0111","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s40279-023-01918-w","article-title":"Exercise in the management of metabolic-associated fatty liver disease (MAFLD) in adults: A position statement from exercise and sport science Australia","volume":"53","author":"Keating","year":"2023","journal-title":"Sports Med"},{"key":"10.1016\/j.aohep.2026.102180_bib0112","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155835","article-title":"Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges","volume":"154","author":"Kokkorakis","year":"2024","journal-title":"Metab-Clin Exp"},{"issue":"5","key":"10.1016\/j.aohep.2026.102180_bib0113","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.aohep.2026.102180_bib0114","first-page":"914","article-title":"Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial","volume":"102","author":"Viscoli","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.aohep.2026.102180_bib0115","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s12072-021-10242-2","article-title":"First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients","volume":"15","author":"Huang","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.aohep.2026.102180_bib0116","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.aohep.2026.102180_bib0117","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S2213-8587(13)70050-0","article-title":"SGLT inhibitors in management of diabetes","volume":"1","author":"Tahrani","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.aohep.2026.102180_bib0118","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstr\u00e5le","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10296","key":"10.1016\/j.aohep.2026.102180_bib0119","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.aohep.2026.102180_bib0120","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.aohep.2026.102180_bib0121","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3390\/biomedicines11071875","article-title":"Novel dual incretin receptor agonists in the spectrum of metabolic diseases with a focus on tirzepatide: real game-changers or great expectations? A narrative review","volume":"11","author":"Liarakos","year":"2023","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.aohep.2026.102180_bib0122","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/00365520902845268","article-title":"Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial","volume":"44","author":"Haukeland","year":"2009","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0123","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: a systematic review and meta\u2011analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed Rep"},{"issue":"9756","key":"10.1016\/j.aohep.2026.102180_bib0124","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.aohep.2026.102180_bib0125","article-title":"Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"2013","author":"Eslami","year":"2013","journal-title":"Cochrane Datab System Rev"},{"issue":"9972","key":"10.1016\/j.aohep.2026.102180_bib0126","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"10215","key":"10.1016\/j.aohep.2026.102180_bib0127","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.aohep.2026.102180_bib0128","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","author":"Sanyal","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0129","article-title":"Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance?","volume":"2013","author":"Hafeez","year":"2013","journal-title":"J Obes"},{"issue":"3","key":"10.1016\/j.aohep.2026.102180_bib0130","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.soard.2021.11.015","article-title":"ASMBS position statement on the impact of metabolic and bariatric surgery on nonalcoholic steatohepatitis","volume":"18","author":"Mazzini","year":"2022","journal-title":"Surg Obes Relat Dis"},{"issue":"6","key":"10.1016\/j.aohep.2026.102180_bib0131","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2026.102180_bib0132","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.7188","article-title":"Cardiovascular outcomes and mortality after bariatric surgery in patients with nonalcoholic fatty liver disease and obesity","volume":"6","author":"Krishnan","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0133","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/SLA.0000000000003871","article-title":"Bariatric surgery is associated with decreased progression of nonalcoholic fatty liver disease to cirrhosis: a retrospective cohort analysis","volume":"272","author":"Wirth","year":"2020","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.aohep.2026.102180_bib0134","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/liv.14441","article-title":"Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease: evidence and perspectives","volume":"40","author":"Salomone","year":"2020","journal-title":"Liver Int"},{"issue":"10215","key":"10.1016\/j.aohep.2026.102180_bib0135","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(19)32963-0","article-title":"Obeticholic acid: towards first approval for NASH","volume":"394","author":"Eslam","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.aohep.2026.102180_bib0136","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.14937","article-title":"Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases","volume":"48","author":"Stine","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.aohep.2026.102180_bib0137","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamaoncol.2016.3147","article-title":"MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma","volume":"3","author":"Kim","year":"2017","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.aohep.2026.102180_bib0138","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.aohep.2026.102180_bib0139","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jhep.2010.03.010","article-title":"Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival","volume":"53","author":"Santi","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102180_bib0140","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ajt.15674","article-title":"OPTN\/SRTR 2018 annual data report: liver","volume":"20","author":"Kwong","year":"2020","journal-title":"Am J Transpl"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0141","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/LVT.0000000000000007","article-title":"Outcomes in liver transplant recipients with nonalcoholic fatty liver disease-related HCC: results from the US multicenter HCC transplant consortium","volume":"29","author":"Verna","year":"2023","journal-title":"Liver Transpl"},{"issue":"5","key":"10.1016\/j.aohep.2026.102180_bib0142","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.25855","article-title":"Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events","volume":"56","author":"VanWagner","year":"2012","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0143","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/TP.0000000000002433","article-title":"International liver transplantation consensus statement on end-stage liver disease due to nonalcoholic steatohepatitis and liver transplantation","volume":"103","author":"Tsochatzis","year":"2019","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.aohep.2026.102180_bib0144","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.cgh.2013.06.025","article-title":"Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis","volume":"11","author":"Finkenstedt","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2026.102180_bib0145","first-page":"428","article-title":"Nonalcoholic fatty liver disease after liver transplant","volume":"9","author":"Shetty","year":"2021","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2026.102180_bib0146","first-page":"57","article-title":"Recurrence of disease following liver transplantation: nonalcoholic steatohepatitis vs hepatitis C virus infection","volume":"2","author":"Hanouneh","year":"2011","journal-title":"Int J Organ Transplant Med"},{"issue":"3","key":"10.1016\/j.aohep.2026.102180_bib0147","first-page":"2355","article-title":"Impact of cancer rehabilitation on the prognosis of patients with hepatocellular carcinoma","volume":"19","author":"Hashida","year":"2020","journal-title":"Oncol Lett"},{"issue":"3","key":"10.1016\/j.aohep.2026.102180_bib0148","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4143\/crt.2017.232","article-title":"Sarcopenia predicts prognosis in patients with newly diagnosed hepatocellular carcinoma, independent of tumor stage and liver function","volume":"50","author":"Ha","year":"2018","journal-title":"Cancer Res Treatment: Off J Korean Cancer Assoc"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0149","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cgh.2020.04.083","article-title":"Type 2 diabetes and metformin use associate with outcomes of patients with non-alcoholic steatohepatitis-related, child-pugh A cirrhosis","volume":"19","author":"Vilar-Gomez","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2026.102180_bib0150","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.aohep.2019.11.008","article-title":"Meta-analysis: the efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes","volume":"19","author":"Zhou","year":"2020","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2026.102180_bib0151","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155583","article-title":"Loss of metabolic adaptation in lean MAFLD is driven by endotoxemia leading to epigenetic reprogramming","volume":"144","author":"Alharthi","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.aohep.2026.102180_bib0152","doi-asserted-by":"crossref","DOI":"10.1177\/20420188241252543","article-title":"MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight","volume":"15","author":"Pan","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.aohep.2026.102180_bib0153","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S2468-1253(20)30090-X","article-title":"Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health","volume":"5","author":"Eslam","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2026.102180_bib0154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-024-10701-6","article-title":"Telomere length and mortality in lean MAFLD: the other face of metabolic adaptation","volume":"18","author":"Alarabi","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.aohep.2026.102180_bib0155","article-title":"Identifying the most critical behavioral lifestyles associated with MAFLD: evidence from the NHANES 2017\u20132020","volume":"15","author":"Li","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.aohep.2026.102180_bib0156","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s12519-024-00814-1","article-title":"Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis","volume":"20","author":"Lee","year":"2024","journal-title":"World J Pediatr"},{"issue":"Suppl 2","key":"10.1016\/j.aohep.2026.102180_bib0157","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s12072-024-10691-5","article-title":"Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives","volume":"18","author":"Vimalesvaran","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.aohep.2026.102180_bib0158","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2020.603654","article-title":"New perspectives on genetic prediction for pediatric metabolic associated fatty liver disease","volume":"8","author":"Lin","year":"2020","journal-title":"Front Pediatr"},{"key":"10.1016\/j.aohep.2026.102180_bib0159","article-title":"The impacts of Ramadan fasting for patients with non-alcoholic fatty liver disease (NAFLD): a systematic review","volume":"10","author":"Lin","year":"2024","journal-title":"Front Nutr"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0160","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s43066-022-00187-y","article-title":"Effect of Ramadan fasting on hepatic steatosis as quantified by controlled attenuation parameter (CAP): a prospective observational study","volume":"12","author":"Gad","year":"2022","journal-title":"Egypt Liver J"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0161","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0002-8223(21)14634-6","article-title":"Fasting in Islam","volume":"67","author":"Sakr","year":"1975","journal-title":"J Am Diet Assoc"},{"issue":"4","key":"10.1016\/j.aohep.2026.102180_bib0162","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.gastha.2024.01.018","article-title":"The impact of climate change, pollution and biodiversity loss on digestive health and disease","volume":"3","author":"Leddin","year":"2024","journal-title":"Gastro Hep Adv"},{"issue":"1","key":"10.1016\/j.aohep.2026.102180_bib0163","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10584-016-1665-6","article-title":"Strongly increasing heat extremes in the Middle East and North Africa (MENA) in the 21st century","volume":"137","author":"Lelieveld","year":"2016","journal-title":"Clim Change"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126000013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126000013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:48:39Z","timestamp":1780649319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268126000013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":163,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1665268126000013"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102180","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The African Middle East Association of Gastroenterology (AMAGE) clinical practice guidelines for the diagnosis and management of metabolic dysfunction associated fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102180","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102180"}}